Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

Nuvectis is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting ...

It’s possible to become a millionaire, and it begins with one simple step that’s accessible to many Americans.

Report finds “rampant investor” buys and unprecedented housing appreciation have created an affordable housing shortfall of ...

We recently published a list of the Top 12 Luxury Clothing Stocks to Buy According to Hedge Funds. In this article, we are ...

We recently published a list of the Top 12 Luxury Clothing Stocks to Buy According to Hedge Funds. In this article, we are ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The current market environment suggests that traders should adopt a strategy of "buy the dip and sell the rips." The ...

The last two years have been just about as good as stock investors could have hoped for. Here’s what to expect going forward.

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...